AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K/AKT/mTOR pathway is crucial for cell functions and frequently deregulated in breast cancer.
• AKT signaling plays a key role in various breast cancer subtypes, including HR+, HER2-amplified, and triple-negative tumors.
• Targeting AKT is a promising strategy for breast cancer, particularly for treatment-resistant cases.

Purpose of the Study:

• To review the clinical evidence for AKT inhibitors in breast cancer treatment.
• To summarize efficacy and toxicity data from clinical trials of AKT inhibitors.
• To explore novel combination strategies involving AKT inhibitors for enhanced therapeutic outcomes.

Main Methods:

• Review of clinical trial data for AKT inhibitors (capivasertib, ipatasertib).
• Analysis of efficacy, toxicity, and translational correlates.
• Investigation of ongoing combination trials with other targeted therapies and immunotherapies.

Main Results:

• Capivasertib and ipatasertib have shown promise in Phase I/II trials for breast cancer.
• Phase III trials are underway for these AKT inhibitors in HR+ and triple-negative breast cancer.
• Combination strategies with CDK4/6 inhibitors, immune checkpoint inhibitors, and PARP inhibitors are under active investigation.

Conclusions:

• AKT inhibitors represent a significant therapeutic advancement for diverse breast cancer subtypes.
• Identifying predictive biomarkers for AKT inhibition response remains a critical unmet need.
• Combination therapies hold potential to overcome resistance and improve treatment efficacy in breast cancer.